Literature DB >> 11080536

In vitro and in vivo assay systems for study of influenza virus inhibitors.

R W Sidwell1, D F Smee.   

Abstract

Evaluation of potential influenza virus inhibitors may utilize multiple steps. First would be to determine if the viral target (e.g. influenza virus neuraminidase) being focused upon will be inhibited in the appropriate assay. Standard in vitro antiviral assays, used next in antiviral evaluations, may utilize inhibition of viral plaques, viral cytopathic effect (CPE), and viral hemagglutinin or other protein, with inhibition of viral yield used in follow-up evaluations. The CPE can be determined visually and by dye uptake. Animal models used for study of potential influenza virus inhibitors include the ferret, the laboratory mouse, and the chicken, with a variety of parameters used to indicate the severity of the infection and its inhibition by therapy. Multiple parameters are recommended in any in vivo antiviral evaluation. The ferret and the mouse infection models have been useful in studying the development of drug resistance and the relative virulence of drug-resistant viruses. The influenza mouse model has also been of value for the evaluation of immunomodulating effects of test compounds and for the study of the utility of antiviral drugs for use against influenza virus infections in the immunocompromised host. In considering the use of any animal model, species differences in drug pharmacology and metabolism must be taken into account. This review has described the systems which have been used most frequently by antiviral investigators, using, as examples, recent studies with the clinically approved influenza virus neuraminidase inhibitors oseltamivir and zanamivir.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11080536     DOI: 10.1016/s0166-3542(00)00125-x

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  42 in total

1.  Identification of a small-molecule entry inhibitor for filoviruses.

Authors:  Arnab Basu; Bing Li; Debra M Mills; Rekha G Panchal; Steven C Cardinale; Michelle M Butler; Norton P Peet; Helena Majgier-Baranowska; John D Williams; Ishan Patel; Donald T Moir; Sina Bavari; Ranjit Ray; Michael R Farzan; Lijun Rong; Terry L Bowlin
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

2.  Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system.

Authors:  James J McSharry; Qingmei Weng; Ashley Brown; Robert Kulawy; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

3.  Mutations in influenza virus M1 CCHH, the putative zinc finger motif, cause attenuation in mice and protect mice against lethal influenza virus infection.

Authors:  Eric Ka-Wai Hui; Donald F Smee; Min-Hui Wong; Debi P Nayak
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

4.  Exacerbation of influenza virus infections in mice by intranasal treatments and implications for evaluation of antiviral drugs.

Authors:  Donald F Smee; Mark von Itzstein; Beenu Bhatt; E Bart Tarbet
Journal:  Antimicrob Agents Chemother       Date:  2012-10-01       Impact factor: 5.191

5.  Treatment of oseltamivir-resistant influenza A (H1N1) virus infections in mice with antiviral agents.

Authors:  Donald F Smee; Justin G Julander; E Bart Tarbet; Matthew Gross; Jack Nguyen
Journal:  Antiviral Res       Date:  2012-07-15       Impact factor: 5.970

Review 6.  Virulence determinants of pandemic influenza viruses.

Authors:  Donna M Tscherne; Adolfo García-Sastre
Journal:  J Clin Invest       Date:  2011-01-04       Impact factor: 14.808

7.  Hydroxylated sclerosporin derivatives from the marine-derived fungus Cadophora malorum.

Authors:  Celso Almeida; Ekaterina Eguereva; Stefan Kehraus; Carsten Siering; Gabriele M König
Journal:  J Nat Prod       Date:  2010-03-26       Impact factor: 4.050

8.  Therapeutic activity of an anti-idiotypic antibody-derived killer peptide against influenza A virus experimental infection.

Authors:  Giorgio Conti; Walter Magliani; Stefania Conti; Lucia Nencioni; Rossella Sgarbanti; Anna Teresa Palamara; Luciano Polonelli
Journal:  Antimicrob Agents Chemother       Date:  2008-09-29       Impact factor: 5.191

9.  Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in mice.

Authors:  David A Boltz; Natalia A Ilyushina; C Shane Arnold; Y Sudhakar Babu; Robert G Webster; Elena A Govorkova
Journal:  Antiviral Res       Date:  2008-06-23       Impact factor: 5.970

Review 10.  Animal models for the study of influenza pathogenesis and therapy.

Authors:  Dale L Barnard
Journal:  Antiviral Res       Date:  2009-01-25       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.